The poor experience of the HTA Review was predictable and predicted. While, in many ways, it might be too late to correct, there are valuable lessons that can guide advocacy over the years ahead. The primary lesson is prioritising caution over misplaced and frankly naive enthusiasm for controlled processes run by the all-powerful single-payer.
The process looked like a teddy bear, but a closer look has revealed a hidden risk
March 11, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Medicines Australia announces appointment of new board chair
March 20, 2025 - - Latest News -
The 'Week in Review Dispatched' Podcast - 21 March
March 20, 2025 - - Podcast -
New NZ approval clears the way for expanded access to cystic fibrosis therapy
March 20, 2025 - - Latest News -
The minister and the US-based industry have a lot in common, including their criticisms of the PBS
March 20, 2025 - - Latest News -
Sigma releases final pre-merger full-year result, confirming impact of CW supply contract
March 20, 2025 - - Latest News -
Stakeholder backing for another PBS co-pay reduction
March 20, 2025 - - Latest News -
If our own government isn't going to do anything, then we can only hope for intervention
March 20, 2025 - - Latest News